» Articles » PMID: 37642238

Long Noncoding RNA TUG1 Regulates Smooth Muscle Cell Differentiation Via KLF4-myocardin Axis

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Abdominal aortic aneurysms (AAAs) are asymptomatic vascular diseases that have life-threatening outcomes. Smooth muscle cell (SMC) dysfunction plays an important role in AAA development. The contribution of non-coding genome, specifically the role of long non-coding RNAs (lncRNAs) in SMC dysfunction, is relatively unexplored. We investigated the role of lncRNA TUG1 in SMC dysfunction. To identify potential lncRNAs relevant to SMC functionality, lncRNA profiling was performed in angiotensin-II-treated SMCs. AAA was induced by angiotensin-II treatment in mice. Transcriptional regulation of TUG1 was studied using promoter luciferase and chromatin-immuno-precipitation experiments. Gain-or-loss-of-function experiments were performed in vitro to investigate TUG1-mediated regulation of SMC function. Immunoprecipitation experiments were conducted to elucidate the mechanism underlying TUG1-mediated SMC dysfunction. TUG1 was upregulated in SMCs following angiotensin-II treatment. Similarly, TUG1 levels were elevated in abdominal aorta in a mouse model of angiotensin-II-induced AAA. Further investigations showed that angiotensin-II-induced TUG1 expression could be suppressed by inhibiting Notch-signaling pathway, both in vitro and in mouse AAA model and that TUG1 is a direct transcriptional target of the Notch pathway. In aneurysmal tissues, TUG1 expression was inversely correlated with the expression of SMC contractile genes. Overexpression of TUG1 repressed SMC differentiation in vitro, whereas siRNA/shRNA-mediated TUG1 knockdown showed an opposite effect. Mechanistically, TUG1 interacts with transcriptional repressor KLF4 and facilitates its recruitment to myocardin promoter ultimately leading to the repression of SMC differentiation. In summary, our study uncovers a novel role for the lncRNA TUG1 wherein it modulates SMC differentiation via the KLF4-myocardin axis, which may have potential implications in AAA development. TUG1 is an angiotensin-II-induced long noncoding RNA that mediates smooth muscle cell (SMC) dysfunction through interaction with transcriptional repressor KLF4.

Citing Articles

Long Non-Coding RNA Function in Smooth Muscle Cell Plasticity and Atherosclerosis.

Maegdefessel L, Fasolo F Arterioscler Thromb Vasc Biol. 2024; 45(2):172-185.

PMID: 39633574 PMC: 11748911. DOI: 10.1161/ATVBAHA.124.320393.


Epigenetic modifications in abdominal aortic aneurysms: from basic to clinical.

Liu Y, Sun X, Gou Z, Deng Z, Zhang Y, Zhao P Front Cardiovasc Med. 2024; 11:1394889.

PMID: 38895538 PMC: 11183338. DOI: 10.3389/fcvm.2024.1394889.

References
1.
Katsushima K, Natsume A, Ohka F, Shinjo K, Hatanaka A, Ichimura N . Targeting the Notch-regulated non-coding RNA TUG1 for glioma treatment. Nat Commun. 2016; 7:13616. PMC: 5150648. DOI: 10.1038/ncomms13616. View

2.
Quintana R, Taylor W . Cellular Mechanisms of Aortic Aneurysm Formation. Circ Res. 2019; 124(4):607-618. PMC: 6383789. DOI: 10.1161/CIRCRESAHA.118.313187. View

3.
Creemers E, Sutherland L, McAnally J, Richardson J, Olson E . Myocardin is a direct transcriptional target of Mef2, Tead and Foxo proteins during cardiovascular development. Development. 2006; 133(21):4245-56. DOI: 10.1242/dev.02610. View

4.
Nosoudi N, Nahar-Gohad P, Sinha A, Chowdhury A, Gerard P, Carsten C . Prevention of abdominal aortic aneurysm progression by targeted inhibition of matrix metalloproteinase activity with batimastat-loaded nanoparticles. Circ Res. 2015; 117(11):e80-9. PMC: 4636940. DOI: 10.1161/CIRCRESAHA.115.307207. View

5.
Han F, Wang J, Ding L, Hu Y, Li W, Yuan Z . Tissue Engineering and Regenerative Medicine: Achievements, Future, and Sustainability in Asia. Front Bioeng Biotechnol. 2020; 8:83. PMC: 7105900. DOI: 10.3389/fbioe.2020.00083. View